{"product_id":"global-joint-venture-partnering-terms-and-agreements-in-pharma-biotech-and-diagnostics-2016-2023","title":"Global Joint Venture Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2016-2023","description":"\u003cp\u003eGlobal Joint Venture Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2016-2023\u003c\/p\u003e\n\n\u003cp\u003eThe Global Joint Venture Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2016-2023 report provides comprehensive understanding and unprecedented access to the joint venture deals and agreements entered into by the worlds leading life science companies.\u003c\/p\u003e\n\n\u003cp\u003eThis report provides details of the latest joint venture agreements announced in the pharmaceutical, biotechnology and diagnostic sectors. Fully up to date, the report provides details of joint venture agreements from 2016.\u003c\/p\u003e\n\n\u003cp\u003eThere is an increasing willingness for parties to enter joint venture deals; such deals enable both parties to benefit from the upside of a big product win, whereas traditional licensing deals forfeit upside for near term upfront, milestone and royalty payments.\u003c\/p\u003e\n\n\u003cp\u003eJoint venture partnering allow the parties to securitize value and reduce risk, but keep a part of the potential upside should the product reach the market. Event if the licensor does not commercialize the project they can either sell those rights to the licensee partner or another partner for an amount higher than would have been achieved at an earlier stage licensing deal.\u003c\/p\u003e\n\n\u003cp\u003eAnother reason for joint venture deals is the joint origin of a project. Drug development projects often require various scientific and technological novelties that stem from different companies. If both companies contributed to the origination of the project, then both have from the beginning a stake in the project.\u003c\/p\u003e\n\n\u003cp\u003eThe report provides a detailed understanding and analysis of how and why companies enter joint venture deals.\u003c\/p\u003e\n\n\u003cp\u003eUnderstanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases and databases do not.\u003c\/p\u003e\n\n\u003cp\u003eThis report contains a comprehensive listing of all joint venture deals announced since 2016 as recorded in the Current Agreements deals and alliances database, including financial terms where available, plus links to online copies of actual joint venture contract documents as submitted to the Securities Exchange Commission by companies and their partners.\u003c\/p\u003e\n\n\u003cp\u003eContract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal.\u003c\/p\u003e\n\n\u003cp\u003eThe initial chapters of this report provide an orientation of joint venture dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an analysis of the trends in joint venture as well as a discussion on the merits of the type of deal.\u003c\/p\u003e\n\n\u003cp\u003eChapter 3 provides an overview of the structure of joint venture deals. The chapter includes numerous case studies to enable understanding of joint venture deals.\u003c\/p\u003e\n\n\u003cp\u003eChapter 4 provides a review of the leading Joint venture deals since 2016. Deals are listed by headline value. Where the deal has an agreement contract published at the SEC a link provides online access to the contract via the Current Agreements deals and alliances database.\u003c\/p\u003e\n\n\u003cp\u003eChapter 5 provides a comprehensive listing of the top 25 most active Joint venture dealmaker companies. Each deal title links via Current Agreements deals and alliances database to an online version of the full deal record, and where available, the actual contract document, providing easy access to each deal record on demand.\u003c\/p\u003e \n\n\u003cp\u003eChapter 6 provides a comprehensive and detailed review of Joint venture deals organized by company A-Z, therapy, technology and industry type signed and announced since 2016 where a contract document is available. Contract documents provide an indepth insight into the actual deal terms agreed between the parties with respect to the Joint venture deal.\u003c\/p\u003e\n\n\u003cp\u003eThe appendices to the report includes a comprehensive listing of all Joint venture deals announced since 2016. Each listing is organized as an appendix by company A-Z, stage of development at signing, therapeutic area and industry type. Each deal title links via hyperlink to an online version of the deal record including, where available, the actual contract document.\u003c\/p\u003e\n\n\u003cp\u003eThe report also includes numerous table and figures that illustrate the trends and activities in Joint venture dealmaking since 2016.\u003c\/p\u003e\n\n\u003cp\u003eIn conclusion, this report provides everything a prospective dealmaker needs to know about Joint venture alliances.\u003c\/p\u003e\n\n\u003cp\u003eKey benefits\u003c\/p\u003e\n\n\u003cp\u003eGlobal Joint Venture Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2016-2023 provides the reader with the following key benefits:\u003c\/p\u003e\n\n\u003cp\u003eIn-depth understanding of joint venture partnering deal trends since 2016, with real life case studies\u003cbr\u003e\nComprehensive listing of all joint venture deals since 2016, together with deal terms, value and press release\u003cbr\u003e\nComprehensive access to actual joint venture contracts entered into by the world’s life science companies\u003cbr\u003e\nInsight into the terms included in a joint venture agreement, together with real world clause examples\u003cbr\u003e\nUnderstand the key deal terms companies have agreed in previous deals           \u003cbr\u003e\nUndertake due diligence to assess suitability of your proposed deal terms for partner companies\u003c\/p\u003e\u003cbr\u003e\n \n\n\u003cp\u003eReport scope\u003c\/p\u003e\n\n\u003cp\u003eGlobal Joint Venture Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2016-2023 is intended to provide the reader with an in-depth understanding of the joint venture trends and structure of deals entered into by leading life science companies worldwide.\u003c\/p\u003e         \n\n\u003cp\u003eGlobal Joint Venture Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2016-2023 includes:\u003c\/p\u003e\n\n\u003cp\u003eTrends in joint venture dealmaking in the biopharma industry since 2016\u003cbr\u003e\nCase studies of real-life joint venture deals\u003cbr\u003e\nComprehensive listing of joint venture deals since 2016\u003cbr\u003e\nAccess to joint venture contract documents\u003cbr\u003e\nThe leading joint venture deals by value since 2016\u003cbr\u003e\nMost active joint venture dealmakers since 2016\u003cbr\u003e\nThe leading joint venture partnering resources\u003c\/p\u003e\u003cbr\u003e\n \n\n\u003cp\u003eIn Global Joint Venture Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2016-2023 available deals and contracts are listed by:\u003c\/p\u003e\n\n\u003cp\u003eCompany A-Z\u003cbr\u003e\nHeadline value\u003cbr\u003e\nTherapeutic area\u003cbr\u003e\nTechnology type\u003cbr\u003e\n \u003cbr\u003e\nEach deal title links via Weblink to an online version of the actual deal record and where available, contract document, providing easy access to each contract document on demand.\u003c\/p\u003e\n\n\u003cp\u003eThe Global Joint Venture Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2016-2023 report provides comprehensive access to available contract documents for joint venture deals. Analyzing actual contract agreements allows assessment of the following:\u003c\/p\u003e\n\n\u003cp\u003eWhat are the precise rights granted or optioned?\u003cbr\u003e\nWhat is actually granted by the agreement to the partner company?\u003cbr\u003e\nWhat exclusivity is granted?\u003cbr\u003e\nWhat is the payment structure for the deal?\u003cbr\u003e\nHow do milestone align with clinical stage development phases?\u003cbr\u003e\nHow are sales and payments audited?\u003cbr\u003e\nWhat is the deal term?\u003cbr\u003e\nHow are the key terms of the agreement defined?\u003cbr\u003e\nHow are IPRs handled and owned?\u003cbr\u003e\nWho is responsible for commercialization?\u003cbr\u003e\nWho is responsible for development, supply, and manufacture?\u003cbr\u003e\nHow is confidentiality and publication managed?\u003cbr\u003e\nHow are disputes to be resolved?\u003cbr\u003e\nUnder what conditions can the deal be terminated?\u003cbr\u003e\nWhat happens when there is a change of ownership?\u003cbr\u003e\nWhat sublicensing and subcontracting provisions have been agreed?\u003cbr\u003e\nWhich boilerplate clauses does the company insist upon?\u003cbr\u003e\nWhich boilerplate clauses appear to differ from partner to partner or deal type to deal type?\u003cbr\u003e\nWhich jurisdiction does the company insist upon for agreement law?\u003c\/p\u003e","brand":"Life Science","offers":[{"title":"April, 2023 \/ 350 Pages \/ MCW16229078","offer_id":47646912282930,"sku":null,"price":4794.0,"currency_code":"USD","in_stock":true},{"title":"April, 2023 \/ 350 Pages \/ MCW16229079","offer_id":47646912315698,"sku":null,"price":4794.0,"currency_code":"USD","in_stock":true}],"url":"https:\/\/www.hardmanwell.com\/products\/global-joint-venture-partnering-terms-and-agreements-in-pharma-biotech-and-diagnostics-2016-2023","provider":"HARDMAN AND WELL MANAGEMENT CONSULTANCIES L.L.C","version":"1.0","type":"link"}